Zobrazeno 1 - 10
of 58
pro vyhledávání: '"JAMES P. MANCUSO"'
Autor:
Margaret E. Brousseau, John S. Millar, Margaret R. Diffenderfer, Chorthip Nartsupha, Bela F. Asztalos, Megan L. Wolfe, James P. Mancuso, Andres G. Digenio, Daniel J. Rader, Ernst J. Schaefer
Publikováno v:
Journal of Lipid Research, Vol 50, Iss 7, Pp 1456-1462 (2009)
This study was designed to establish the mechanism responsible for the increased apolipoprotein (apo) A-II levels caused by the cholesteryl ester transfer protein inhibitor torcetrapib. Nineteen subjects with low HDL cholesterol (
Externí odkaz:
https://doaj.org/article/136923cae7b94b1d8203c6d7c1c787a6
Autor:
John S. Millar, Margaret E. Brousseau, Margaret R. Diffenderfer, P. Hugh R. Barrett, Francine K. Welty, Jeffrey S. Cohn, Aisha Wilson, Megan L. Wolfe, Chorthip Nartsupha, Peter M. Schaefer, Andres G. Digenio, James P. Mancuso, Gregory G. Dolnikowski, Ernst J. Schaefer, Daniel J. Rader
Publikováno v:
Journal of Lipid Research, Vol 49, Iss 3, Pp 543-549 (2008)
Cholesteryl ester transfer protein (CETP) inhibition leads to changes in lipoprotein metabolism. We studied the effect of the CETP inhibitor torcetrapib on VLDL apolipoprotein E (apoE) metabolism. Subjects, pretreated with atorvastatin (n = 9) or unt
Externí odkaz:
https://doaj.org/article/a04a79f8a7cf41729eb1fdd834ca518e
Autor:
Mary Wandia Kivata, Margaret Mbuchi, Fredrick Lunyagi Eyase, Wallace Dimbuson Bulimo, Cecilia Katunge Kyanya, Valerie Oundo, Simon Wachira Muriithi, Ben Andagalu, Wilton Mwema Mbinda, Olusegun O. Soge, R. Scott McClelland, Willy Sang, James D. Mancuso
Publikováno v:
BMC Microbiology, Vol 19, Iss 1, Pp 1-9 (2019)
Abstract Background Phenotypic fluoroquinolone resistance was first reported in Western Kenya in 2009 and later in Coastal Kenya and Nairobi. Until recently gonococcal fluoroquinolone resistance mechanisms in Kenya had not been elucidated. The aim of
Externí odkaz:
https://doaj.org/article/4f3d56e154814296849477114882c00c
Autor:
Brian S. Wojeck, Silvio E. Inzucchi, Ian J. Neeland, James P. Mancuso, Robert Frederich, Urszula Masiukiewicz, Nilo B. Cater, Darren K. McGuire, Christopher P. Cannon, Henry Klar Yaggi
Publikováno v:
Sleep and Breathing. 27:669-672
Purpose The sodium-glucose transporter 2 inhibitor (SGLT2i) empagliflozin may reduce the incidence of obstructive sleep apnea (OSA) in patients with type 2 diabetes (T2D) and cardiovascular (CV) disease. This analysis of VERTIS CV, the CV outcome tri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e18ef7438f11494436b2f7e3f6902713
https://doi.org/10.1007/s11325-022-02594-2
https://doi.org/10.1007/s11325-022-02594-2
Autor:
Samuel Dagogo‐Jack, Christopher P. Cannon, David Z. I. Cherney, Francesco Cosentino, Jie Liu, Annpey Pong, Ira Gantz, Robert Frederich, James P. Mancuso, Richard E. Pratley
Publikováno v:
Diabetes, Obesity and Metabolism. 24:1245-1254
To assess selected cardiorenal outcomes with ertugliflozin according to use of baseline glucose-lowering agent.VERTIS CV was a cardiovascular (CV) outcome trial for ertugliflozin versus placebo, conducted in patients with type 2 diabetes and establis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8424c5e3728d5097ba0aa293273afa0
https://doi.org/10.1111/dom.14691
https://doi.org/10.1111/dom.14691
Autor:
Francesco Cosentino, Christopher P. Cannon, Robert Frederich, David Z.I. Cherney, Samuel Dagogo-Jack, Richard E. Pratley, James P. Mancuso, Mario Maldonado, Nilo B. Cater, Shuai Wang, Darren K. McGuire
Publikováno v:
Circulation. 146:652-654
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b7cfe2b94fb193dbdd674a67d5bc88d0
https://doi.org/10.1161/circulationaha.121.058294
https://doi.org/10.1161/circulationaha.121.058294
Autor:
Joseph M. Kim, Deepak L. Bhatt, Samuel Dagogo‐Jack, David Z. I. Cherney, Francesco Cosentino, Darren K. McGuire, Richard E. Pratley, Chih‐Chin Liu, Nilo B. Cater, Robert Frederich, James P. Mancuso, Christopher P. Cannon
Publikováno v:
Diabetes, obesitymetabolism.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::252871282c91088dac94ce361cb763ad
https://pubmed.ncbi.nlm.nih.gov/36594154
https://pubmed.ncbi.nlm.nih.gov/36594154
Autor:
Jason M Lempp, Margan J Zajdowicz, Arlene L Hankinson, Sean R Toney, Lisa W Keep, James D Mancuso, Gerald H Mazurek
Publikováno v:
PLoS ONE, Vol 12, Iss 5, p e0177752 (2017)
BACKGROUND:Immunologic tests such as the tuberculin skin test (TST) and QuantiFERON®-TB Gold In-Tube test (QFT-GIT) are designed to detect Mycobacterium tuberculosis infection, both latent M. tuberculosis infection (LTBI) and infection manifesting a
Externí odkaz:
https://doaj.org/article/72e551ef9d304db3ac2ad07fcce87c86
Autor:
SAMUEL DAGOGO-JACK, CHRISTOPHER P. CANNON, DAVID CHERNEY, FRANCESCO COSENTINO, DARREN K. MCGUIRE, JIE LIU, CHIH-CHIN LIU, ROBERT FREDERICH, JAMES P. MANCUSO, RICHARD E. PRATLEY
Publikováno v:
Diabetes. 71
This analysis assessed the incidence and total events of hypoglycemia in VERTIS CV (NCT01986881) , the cardiovascular (CV) outcome trial for ertugliflozin (ERTU) in patients (pts) with type 2 diabetes and atherosclerotic CV disease. Hypoglycemia was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ae90f1a7b47a03a60f3e6066973837ae
https://doi.org/10.2337/db22-865-p
https://doi.org/10.2337/db22-865-p
Autor:
VIKAS S. SRIDHAR, FRANCESCO COSENTINO, SAMUEL DAGOGO-JACK, RICHARD E. PRATLEY, ROBERT FREDERICH, MARGARET N. ESSEX, MARIO MALDONADO, CHIH-CHIN LIU, JAMES P. MANCUSO, DAVID CHERNEY
Publikováno v:
Diabetes. 71
The effect of ertugliflozin (ERTU) on serum uric acid (SUA) and gout-related outcomes in VERTIS CV (NCT01986881) was investigated. Patients with T2D and ASCVD were randomized to ERTU 5 mg (n=2752) , 15 mg (n=2747) (doses pooled for analyses) , placeb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c967d6a50d58fd07a1e2e3caaec8e77
https://doi.org/10.2337/db22-859-p
https://doi.org/10.2337/db22-859-p